Keros Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
KROS$9.17-2.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| DECEMBER 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $331,147 | $279,048 |
| Accounts receivable | 143 | — |
| Prepaid expenses and other current assets | 16,003 | 6,719 |
| Total current assets | 347,293 | 285,767 |
| Operating lease right-of-use assets | 15,334 | 15,548 |
| Property and equipment, net | 4,134 | 2,021 |
| Restricted cash | 1,212 | 1,327 |
| Other long term assets | 2,052 | 2,118 |
| TOTAL ASSETS | $370,025 | $306,781 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES: | ||
| Accounts payable | $5,450 | $3,339 |
| Current portion of operating lease liabilities | 1,005 | 455 |
| Accrued expenses and other current liabilities | 17,918 | 12,753 |
| Total current liabilities | 24,373 | 16,547 |
| Operating lease liabilities, net of current portion | 13,439 | 12,811 |
| Total liabilities | 37,812 | 29,358 |
| COMMITMENTS AND CONTINGENCIES (Note 11) | ||
| STOCKHOLDERS’ EQUITY: | ||
| Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; no shares issued and outstanding | — | — |
| Common stock, par value of $0.0001 per share; 200,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 31,841,084 and 27,543,453 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | 3 | 2 |
| Additional paid-in capital | 713,636 | 505,855 |
| Accumulated deficit | (381,426) | (228,434) |
| Total stockholders’ equity | 332,213 | 277,423 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $370,025 | $306,781 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.